|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
|
|---|---|---|---|---|---|---|---|---|
| Assets [abstract] | ||||||||
| Non-current assets [abstract] | ||||||||
| Property, plant and equipment | ||||||||
| Right-of-use assets | ||||||||
| Goodwill | ||||||||
| Intangible assets other than goodwill | ||||||||
| Investments in associated companies | ||||||||
| Deferred tax assets | ||||||||
| Financial assets | ||||||||
| Other non-current assets | ||||||||
| Total non-current assets | ||||||||
| Current assets [abstract] | ||||||||
| Inventories | ||||||||
| Total trade receivables, net | ||||||||
| Income tax receivables | ||||||||
| Marketable securities, time deposits and derivative financial instruments | ||||||||
| Cash and cash equivalents | ||||||||
| Other current assets | ||||||||
| Total current assets | ||||||||
| Total assets | ||||||||
| Equity and liabilities [abstract] | ||||||||
| Equity [abstract] | ||||||||
| Share capital | ||||||||
| Treasury shares | ||||||||
| Reserves | ||||||||
| Equity attributable to Novartis AG shareholders | ||||||||
| Non-controlling interests | ||||||||
| Total equity | ||||||||
| Liabilities [abstract] | ||||||||
| Non-current liabilities [abstract] | ||||||||
| Financial debts | ||||||||
| Lease liabilities | ||||||||
| Deferred tax liabilities | ||||||||
| Provisions and other non-current liabilities | ||||||||
| Total non-current liabilities | ||||||||
| Current liabilities [abstract] | ||||||||
| Trade payables | ||||||||
| Financial debts and derivative financial instruments | ||||||||
| Lease liabilities | ||||||||
| Current income tax liabilities | ||||||||
| Provisions and other current liabilities | ||||||||
| Total current liabilities | ||||||||
| Total liabilities | ||||||||
| Total equity and liabilities | ||||||||
Loading...
